Analysis of stemness gene expression and CD133 abnormal methylation in neuroblastoma cell lines

Oncology Reports

Volumn 24, Issue 5, 2010, Pages 1355-1362

  Schiapparelli, Paula ^a   Enguita Germán, Mónica ^a   Balbuena, Jana ^a   Rey, Juan A ^b   Lázcoz, Paula ^c   Castresana, Javier S ^a  

^a UNIVERSITY OF NAVARRA   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c PUBLIC UNIVERSITY OF NAVARRE   (Spain)

Author keywords

CD133; Epigenetics; Neural stem cells; Neuroblastoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BMI1 PROTEIN; CD133 ANTIGEN; CD44V ANTIGEN; DNA; FAS ANTIGEN; NESTIN; RNA; TRANSCRIPTION FACTOR SOX2; VIMENTIN;

ARTICLE; CANCER CELL CULTURE; CANCER RELAPSE; CANCER THERAPY; CELL SUBPOPULATION; DEMETHYLATION; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; GENE EXPRESSION; METASTASIS; NEUROBLASTOMA; ONCOGENE C KIT; PRIORITY JOURNAL; PROMOTER REGION; REAL TIME POLYMERASE CHAIN REACTION;

ANTIGENS, CD; CELL LINE, TUMOR; DNA METHYLATION; EPIGENOMICS; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; NEOPLASTIC STEM CELLS; NEUROBLASTOMA; PEPTIDES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78149309989     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000993     Document Type: Article

References (37)

1. Grimmer MR and Weiss WA: Childhood tumors of the nervous system as disorders of normal development. Curr Opin Pediatr 18: 634-638, 2006.
2. Polyak K and Hahn WC: Roots and stems: stem cells in cancer. Nat Med 12: 296-300, 2006.
3. Hemmati HD, Nakano I, Lazareff JA, et al: Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 100: 15178-15183, 2003.
4. Johnsen JI, Kogner P, Albihn A and Henriksson MA: Embryonal neural tumours and cell death. Apoptosis 14: 424-438, 2009.
5. Lasky JL III, Choe M and Nakano I: Cancer stem cells in pediatric brain tumors. Curr Stem Cell Res Ther 4: 298-305, 2009.
6. Mahller YY, Williams JP, Baird WH, et al: Neuroblastoma cell lines contain pluripotent tumor initiating cells that are susceptible to a targeted oncolytic virus. PLoS One 4: e4235, 2009.
7. Maris JM, Hogarty MD, Bagatell R and Cohn SL: Neuroblastoma. Lancet 369: 2106-2120, 2007.
8. Walton JD, Kattan DR, Thomas SK, et al: Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 6: 838-845, 2004.
9. Corbeil D, Fargeas CA and Huttner WB: Rat prominin, like its mouse and human orthologues, is a pentaspan membrane glycoprotein. Biochem Biophys Res Commun 285: 939-944, 2001.
10. Miraglia S, Godfrey W, Yin AH, et al: A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 90: 5013-5021, 1997.
11. Yin AH, Miraglia S, Zanjani ED, et al: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90: 5002-5012, 1997.
12. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951, 2005.
13. Ogden AT, Waziri AE, Lochhead RA, et al: Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62: 505-514, 2008.
14. Ponnusamy MP and Batra SK: Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 1: 4, 2008.
15. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432: 396-401, 2004.
16. Shmelkov SV, Jun L, St Clair R, et al: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 103: 2055-2061, 2004.
17. Feinberg AP and Tycko B: The history of cancer epigenetics. Nat Rev Cancer 4: 143-153, 2004.
18. Herman JG and Baylin SB: Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349: 2042-2054, 2003.
19. Baba T, Convery PA, Matsumura N, et al: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28: 209-218, 2009.
20. Tabu K, Sasai K, Kimura T, et al: Promoter hypomethylation regulates CD133 expression in human gliomas. Cell Res 18: 1037-1046, 2008.
21. Yi JM, Tsai HC, Glockner SC, et al: Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 68: 8094-8103, 2008.
22. Ootsuka S, Asami S, Sasaki T, et al: Analyses of novel prognostic factors in neuroblastoma patients. Biol Pharm Bull 30: 2294-2299, 2007.
23. Ross RA and Spengler BA: Human neuroblastoma stem cells. Semin Cancer Biol 17: 241-247, 2007.
24. Mizrak D, Brittan M and Alison MR: CD133: molecule of the moment. J Pathol 214: 3-9, 2008.
25. Thomas SK, Messam CA, Spengler BA, Biedler JL and Ross RA: Nestin is a potential mediator of malignancy in human neuroblastoma cells. J Biol Chem 279: 27994-27999, 2004.
26. Nakano I, Masterman-Smith M, Saigusa K, et al: Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res 86: 48-60, 2008.
27. Nakano I, Paucar AA, Bajpai R, et al: Maternal embryonic leucine zipper kinase (MELK) regulates multipotent neural progenitor proliferation. J Cell Biol 170: 413-427, 2005.
28. Iwama A, Oguro H, Negishi M, et al: Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product BMI-1. Immunity 21: 843-851, 2004.
29. Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF and Morrison SJ: BMI-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962-967, 2003.
30. Cui H, Hu B, Li T, et al: BMI-1 is essential for the tumorigenicity of neuroblastoma cells. Am J Pathol 170: 1370-1378, 2007.
31. Lee TI, Jenner RG, Boyer LA, et al: Control of developmental regulators by Polycomb in human embryonic stem cells. Cell 125: 301-313, 2006.
32. Masui S, Nakatake Y, Toyooka Y, et al: Pluripotency governed by Sox2 via regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol 9: 625-635, 2007.
33. Rodriguez-Pinilla SM, Sarrio D, Moreno-Bueno G, et al: Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. Mod Pathol 20: 474-481, 2007.
34. Schmitz M, Temme A, Senner V, et al: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 96: 1293-1301, 2007.
35. Maslov AY, Barone TA, Plunkett RJ and Pruitt SC: Neural stem cell detection, characterization, and age-related changes in the subventricular zone of mice. J Neurosci 24: 1726-1733, 2004.
36. Nakano A, Kanemura Y, Mori K, et al: Expression of the Neural RNA-binding protein Musashi1 in pediatric brain tumors. Pediatr Neurosurg 43: 279-284, 2007.
37. Hirschmann-Jax C, Foster AE, Wulf GG, et al: A distinct 'side population' of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci USA 101: 14228-14233, 2004.